KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Revenue (2016 - 2025)

Historic Revenue for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $69.5 million.

  • Rigel Pharmaceuticals' Revenue rose 2559.35% to $69.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.1 million, marking a year-over-year increase of 7912.54%. This contributed to the annual value of $179.3 million for FY2024, which is 5338.38% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Revenue is $69.5 million, which was up 2559.35% from $101.7 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Revenue registered a high of $101.7 million during Q2 2025, and its lowest value of $16.7 million during Q1 2022.
  • Moreover, its 5-year median value for Revenue was $29.8 million (2022), whereas its average is $41.6 million.
  • In the last 5 years, Rigel Pharmaceuticals' Revenue plummeted by 7934.41% in 2022 and then skyrocketed by 17601.04% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Revenue (Quarter) stood at $20.4 million in 2021, then skyrocketed by 151.25% to $51.3 million in 2022, then crashed by 30.2% to $35.8 million in 2023, then skyrocketed by 60.92% to $57.6 million in 2024, then increased by 20.6% to $69.5 million in 2025.
  • Its last three reported values are $69.5 million in Q3 2025, $101.7 million for Q2 2025, and $53.3 million during Q1 2025.